Spyre Therapeutics, Inc.

What they do

Spyre runs clinical development of long-acting antibody candidates — SPY001 (α4β7), SPY002 (TL1A), SPY003 (IL-23) and SPY072 (anti-TL1A) — engineered with YTE substitutions for extended half-life. The company is evaluating these as monotherapies and as pairwise fixed-dose combinations in ulcerative colitis, plus SPY072 in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis. It has no approved products and reports no revenue; operations are funded through equity capital.

Revenue drivers

• Product sales — None. Annual revenue was $0.00 in 2024 and 2025, and quarterly revenue was $0.00 in each quarter of 2024; the company has never generated revenue from product sales.
• SKYLINE Phase 2 (ulcerative colitis) — Investigator- and company-funded clinical program in moderately to severely active UC testing SPY001, SPY002, SPY003 and three pairwise combinations; no revenue, costs are the main cash use.
• SKYWAY Phase 2 basket (rheumatic disease) — Phase 2 basket trial of SPY072 in RA, PsA and axSpA; enrollment is complete across all three sub-studies; no revenue generated.
• Combination franchise — Fixed-dose combinations of the three IBD antibodies are the intended commercial differentiator, but they remain investigational and unmonetized.

Recent performance

Reported second quarter 2026 results on August 4, 2026. Part A topline induction data for SPY001 and SPY002 in ulcerative colitis were presented in April 2026 and June 2026: both met their primary endpoints with statistically significant Robarts Histopathology Index reductions of 9.2 and 10.7 points, and clinical remission/endoscopic improvement rates of 40%/51% and 33%/42%, respectively. Net loss was $155.2M for full-year 2025, and operating cash use was $169.3M in 2025. Balance sheet at June 30, 2026: total assets $1.17B, total liabilities $71.9M, shareholders' equity $1.10B, cash and equivalents $162.0M, with $1.1B in cash, cash equivalents and marketable securities. Enrollment in Part A of SKYLINE is complete and Part B is enrolling; SKYWAY enrollment is complete.

Strategy

The company states three pillars: advance next-generation monotherapies optimized for potency, selectivity and half-life; evaluate paired fixed-dose combinations in IBD; and expand the anti-TL1A program into RA, PsA and axSpA. It is running SKYLINE Part B as a randomized, placebo-controlled dose-ranging and combination proof-of-concept study and SKYWAY as a basket trial in three rheumatic diseases. Management guides to six Phase 2 proof-of-concept readouts in 2026 and says cash supports operations into the second half of 2029. Stated goals include quarterly or twice-yearly subcutaneous maintenance dosing and potential pivotal development of SPY072 in 2027.

Risks

• No revenue and going-concern dependence — The 10-K risk factors state the company will not be able to continue as a going concern if it cannot raise additional capital when needed, and it has never generated product sales revenue.
• Early-stage clinical failure — All programs are Phase 1/2 or preclinical and the 10-K states they may fail, be delayed or cost more than anticipated, including through regulatory disagreement on data sufficiency.
• Concentration in four programs — The 10-K states the company is substantially dependent on the success of SPY001, SPY002, SPY072 and SPY003, alone or in combination, and may miss expected development timelines.
• Combination therapy unproven — The 10-K warns the company may not succeed in developing intra-portfolio combinations to achieve superior outcomes versus other therapies, and no head-to-head trials have been conducted against comparator antibodies.

Outlook

Management guides to six Phase 2 proof-of-concept readouts in 2026: SPY003 Part A data from SKYLINE and the RA sub-study of SKYWAY expected in September, with PsA and axSpA sub-studies in the fourth quarter. SKYLINE Part B induction data are expected in 2027. If SPY072 succeeds in RA, management says it looks to initiate pivotal development in 2027 and explore combinations outside IBD. Cash runway is stated as into the second half of 2029, with all figures forward-looking.